What looks like a miracle is really a trade. GLP-1 agonists such as semaglutide and tirzepatide trigger insulin secretion, slow gastric emptying and act on hypothalamic appetite circuits, so patients eat less, lose large amounts of weight and show tighter glycemic control.

Those rapid shifts come with a price tag, both literal and biological. Reports of nausea, vomiting and gallbladder disease sit beside early signals on pancreatitis and possible thyroid tumors, while high monthly costs and spotty insurance coverage restrict access even as waiting lists grow.

The most unsettling twist is psychological. Patients who say “I intend to stay on it forever” are not exaggerating, because obesity and type 2 diabetes are chronic disorders of energy homeostasis and incretin signaling, and stopping the drug often leads to weight regain and rising blood glucose.

Supporters call that lifelong management, critics call it dependency, and between them sits a pharmaceutical class quietly redrawing how medicine, insurers and patients define treatment, prevention and personal responsibility.